A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors Meeting Abstract
| Authors: | McKean, M.; Spira, A. I.; Rosen, E.; Subbiah, V.; Moreno, V.; Gambardella, V.; Vieito, M.; Saavedra, O.; Cousin, S.; Cassier, P. A.; Lobbardi, R.; SchoĢnborn-Kellenberger, O.; Hurh, E.; Ruisi, M. M.; Buchbinder, E. I. |
| Abstract Title: | A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS3163 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS3163 -- Meeting was also available virtually -- Source: Cinahl |
